Stoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at HC Wainwright

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock. HC Wainwright's price target indicates a potential upside of 476.69% from the stock's previous close. HC Wainwright also issued estimates for Stoke Therapeutics' Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.22 EPS.

Several other equities analysts have also recently issued reports on STOK. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 18th. Chardan Capital reissued a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of "Buy" and an average price target of $23.00.

Remove Ads

Stoke Therapeutics Stock Performance

Shares of STOK traded down $0.18 during midday trading on Wednesday, hitting $8.15. The company had a trading volume of 1,407,236 shares, compared to its average volume of 839,852. The company's 50-day simple moving average is $9.47 and its 200-day simple moving average is $11.39. The firm has a market capitalization of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1 year low of $6.29 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Equities analysts predict that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company's stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last quarter. Company insiders own 11.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new position in shares of Stoke Therapeutics in the 4th quarter valued at approximately $63,000. Teacher Retirement System of Texas purchased a new position in shares of Stoke Therapeutics in the 4th quarter valued at approximately $113,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Stoke Therapeutics in the 4th quarter valued at approximately $124,000. Tower Research Capital LLC TRC boosted its stake in shares of Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after buying an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.